NanoMedSyn is a biotechnology company developing AMFA glycoligands to leverage the M6PR pathway for precise, efficient delivery of therapeutic conjugates to disease‑relevant cells and tissues. We develop technology that creates new possibilities for antibodies, enzymes, nanoparticles, and other biologics.
By engineering therapeutic conjugates with AMFA glycoligands, we enhance tissue targeting, cellular uptake, and lysosomal delivery, thereby unlocking therapeutic performance where conventional delivery approaches are limited.
Preclinical validation of AMFA technology has shown its broad potential for applications in oncology, immunology, inflammation, and metabolic disorders. A proof of concept in Pompe disease (enzyme replacement therapy) demonstrated improved lysosomal targeting and substrate degradation. AMFA-therapy received Orphan Drug Designation from the EMA, strengthening the clinical and regulatory promise of therapies potentiated by AMFA glycoligands.
Our Team
NanoMedSyn brings together expertise in glycochemistry, drug delivery, protein engineering, and translational science to drive the development of next‑generation targeted therapeutics.
Founders
Marcel Garcia
CEO and co-founder of NanoMedSyn
Dr M. Garcia is a former academic research director at INSERM. He initiated studies on the role of steroid hormones and lysosomal enzymes in breast cancer progression, and then explored nanomedicine innovations for lysosomal targeting of therapeutic enzymes, nanoparticles and antibodies through the mannose 6-phosphate receptor pathway. After his academic career, he joined NanoMedSyn as CSO in 2018, and became CEO in 2020.
Alain Morère
Professor, co-founder and scientific advisor of NanoMedSyn
Alain Morère is Professor of Chemistry at the University of Montpellier. His research work focuses on organic chemistry for the design and development of molecular tools dedicated to biological applications and processes. He is an expert in glycochemistry, development and synthesis of carbohydrate analogues and glyco-conjugates for cell targeting, receptor-ligand recognition, drug carriers and drug delivery. He is currently co–leader of the Glyco and Nanovectors for Therapeutic Targeting team.
_
Jean-Olivier Durand
CNRS researcher, co-founder and scientific advisor of NanoMedSyn
Dr Jean-Olivier Durand is an academic research director at the ICGM, Montpellier. Over the past 25 years, he has developed an expertise in the field of organic chemistry applied to healthcare. His research skills are specific to nanoparticles, which have been developed for peptidic micro-array, photodynamic therapy and also for photo-controlled drug delivery. He is also interested in nucleic acids and the potential of transfection of nucleic acids with nanoparticles.
_
Magali Gary-Bobo
CNRS research director, co-founder and scientific advisor of NanoMedSyn
Dr Magali Gary-Bobo is an academic researcher from the CNRS specialized in biotechnologies and targeted therapies, and is a co- founder of NanoMedSyn. Through her research work, she has developed expertise in the drug delivery, lysosomal targeting for enzymotherapy and photodynamic therapy of cancers. Earlier in her career, she worked at Sanofi-Aventis, where she was involved in the development of Acomplia® for obesity treatment. She is currently co–leader of the Glyco and Nanovectors for Therapeutic Targeting team.
Scientific board
Sylvain Yon
Mabqi CEO and co-founder of several companies. Renowned expert in: evaluation and transfer of industrial innovation.
Benoit Dubuis
Professor, Development Director Wyss Center, Campus Biotech (Geneva, Switzerland). Renowned expert in: pharmaceuticals and biotechnology development.
Martine Cerutti
Research director at CNRS. Renowned expert in: baculovirus expression system, recombinant protein engineering and therapy.
Catherine Caillaud
Professor, Inserm / Hopital Necker -Enfants Malades. Renowned expert in: inherited metabolism disorders and lysosomal storage disorders.
Amine A. Kamen
Professor, Canada research chair in bioprocessing of viral vaccines. Renowned expert in: protein engineering and nanoparticles for drug delivery.